+44 20 8123 2220
info@marketpublishers.com

Respiratory syncytial virus infections - Pipeline Insight, 2021

https://marketpublishers.com/r/R4E38A09F589EN.html
Date: June 2021
Pages: 60
Price: US$ 2,500.00 (Single User License)
ID: R4E38A09F589EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Respiratory syncytial virus infections - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory syncytial virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Respiratory syncytial virus infections Understanding

Respiratory syncytial virus infections: Overview

Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract,

+44 20 8123 2220
info@marketpublishers.com

most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.

'Respiratory syncytial virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory syncytial virus infections pipeline landscape is provided which includes the disease overview and Respiratory syncytial virus infections treatment guidelines. The assessment part of the report embraces, in depth Respiratory syncytial virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory syncytial virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

> The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus infections.

Respiratory syncytial virus infections Emerging Drugs Chapters

This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory syncytial virus infections Emerging Drugs

> GSK3844766A: GlaxoSmithKline

This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen

+44 20 8123 2220
info@marketpublishers.com

(RSVPreF3) combined with GSK's proprietary AS01 adjuvant, which is also used in GSK's shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory syncytial virus infections.

Nirsevimab (MEDI-8897): MedImmune

MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.

Sisunatovir: ReViral

Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations

Further product details are provided in the report..

Respiratory syncytial virus infections: Therapeutic Assessment

This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Respiratory syncytial virus infections

There are approx. 50+ key companies which are developing the therapies for Respiratory syncytial virus infections. The companies which have their Respiratory syncytial virus infections drug candidates in the most advanced stage, i.e. phase III

+44 20 8123 2220
info@marketpublishers.com

include, GlaxoSmithKline.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Respiratory syncytial virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

+44 20 8123 2220
info@marketpublishers.com

- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory syncytial virus infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory syncytial virus infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory syncytial virus infections drugs.

Respiratory syncytial virus infections Report Insights

- Respiratory syncytial virus infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

+44 20 8123 2220
info@marketpublishers.com

Respiratory syncytial virus infections Report Assessment

- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Respiratory syncytial virus infections drugs?
- How many Respiratory syncytial virus infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory syncytial virus infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Respiratory syncytial virus infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Respiratory syncytial virus infections and their status?
- What are the key designations that have been granted to the emerging drugs?

+44 20 8123 2220
info@marketpublishers.com

Key Players

GlaxoSmithKline

MedImmune

ReViral

Pfizer

Sanofi

BioComo

IMV

Shionogi

Aridis Pharmaceuticals

ADMA Biologics

Enanta Pharmaceuticals

Merck Sharp & Dohme

Janssen Research & Development

Ark Biosciences

BlueWillow Biologics

Meissa Vaccines

Alios BioPharma

Codagenix

Advance Vaccine Laboratories

+44 20 8123 2220
info@marketpublishers.com

Bavarian Nordic

ModernaTX, Inc.

Virometix

Airway Therapeutics LLC

AlloVir Inc

Anima Biotech Inc

Aridis Pharmaceuticals Inc

Atea Pharmaceuticals Inc

Atriva Therapeutics

Calder Biosciences Inc

Cidara Therapeutics Inc

Clover Biopharmaceuticals

Curevac AG

Enyo Pharma SA

HanaVax Inc.

Icosavax Inc

IDBiologics Inc

Pneumagen Ltd

Riboscience LLC

+44 20 8123 2220
info@marketpublishers.com

Signia Therapeutics

Key Products

GSK3844766A

Nirsevimab (MEDI-8897)

Sisunatovir

RSV F protein vaccine

Novavax

Combination seasonal influenza RSV nanoparticle vaccine

NanoFlu/NVX CoV 2373/RSV

RSVpreF

SP 0125

BC-0004

GSK 3888550A

DPX RSV Vaccine

AR 201

ASCENIV

EDP 938

MK 1654

Rilematovir

+44 20 8123 2220
info@marketpublishers.com

GSK 3003891A

JNJ 64400141

Ziresovir

JNJ 64213175

MV-012-968

ALS-008176

CodaVax-RSV

BARS13

MVA-BN-RSV

mRNA-1345

V-306

ALVR106

AR-201

AT-889

ATR-002

IVX-121

RBS-3149

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Respiratory syncytial virus infections - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/R4E38A09F589EN.html
Price: US$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R4E38A09F589EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970